|
 |
|
|||||||
|
|||||||||
© 2003 by the American Diabetes Association, Inc.
Clinical Care/Education/Nutrition |
One-Year Outcome of a Combination of Weight Loss Therapies for Subjects With Type 2 Diabetes
A randomized trial
From the Division of Endocrinology and Diabetes, Department of Medicine, General Clinical Research Center and Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota
Address correspondence and reprint requests to J. Bruce Redmon, MD, Division of Endocrinology and Diabetes, Department of Medicine, University of Minnesota, MMC 101, 420 Delaware St. SE, Minneapolis, MN 55455. E-mail: redmo001{at}umn.edu
OBJECTIVE—The purpose of this study was to evaluate the effects of a combination weight loss program using intermittent low-calorie diets, energy-controlled meal replacement products, and sibutramine on weight loss, diabetes control, and cardiovascular risk factors in overweight or obese subjects with type 2 diabetes.
RESEARCH DESIGN AND METHODS—Overweight or obese individuals with type 2 diabetes treated with diet or oral medication were randomly assigned to either a standard therapy or combination therapy group. Both groups received a standardized program to facilitate weight loss. The combination therapy group also received 10–15 mg sibutramine daily, low-calorie diets using meal replacement products for 1 week every 2 months, and between low-calorie diet weeks, once daily use of meal replacement product and snack bars to replace one usual meal and snack. Primary outcome measures were changes in body weight, glycemic control, plasma lipids, blood pressure, pulse, and body composition at 1 year.
RESULTS—At 1 year, combination therapy, compared with standard therapy, resulted in significantly more weight loss (-7.3 ± 1.3 kg vs. -0.8 ± 0.9 kg, P < 0.001) and reduction in HbA1c (-0.6 ± 0.3 vs. 0.0 ± 0.2%, P = 0.05). Combination therapy resulted in reduced requirement for diabetes medications and decreased fat mass and lean body mass. A 5-kg decrease in weight at 1 year was associated with a decrease of 0.4% in HbA1c (P = 0.006). Changes in fasting glucose, lipids, pulse, and blood pressure did not differ between groups.
CONCLUSIONS—This combination weight loss program resulted in greater weight loss and improved diabetes control compared with a standard weight loss program in overweight or obese subjects with type 2 diabetes.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  J. B. Redmon, K. P. Reck, S. K. Raatz, J. E. Swanson, C. A. Kwong, H. Ji, W. Thomas, and J. P. Bantle Two-Year Outcome of a Combination of Weight Loss Therapies for Type 2 Diabetes Diabetes Care, June 1, 2005; 28(6): 1311 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Vettor, R. Serra, R. Fabris, C. Pagano, and G. Federspil Effect of Sibutramine on Weight Management and Metabolic Control in Type 2 Diabetes: A meta-analysis of clinical studies Diabetes Care, April 1, 2005; 28(4): 942 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Jayagopal, E. S. Kilpatrick, S. Holding, P. E. Jennings, and S. L. Atkin Orlistat Is as Beneficial as Metformin in the Treatment of Polycystic Ovarian Syndrome J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 729 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Other articles noted: 14 Nov 2003 to 30 Jan 2004 Evid. Based Nurs., April 1, 2004; 7(2): e2 - e2. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |